Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Pharmacogenomics: An evolving clinical tool for precision medicine.

Hockings JK, Pasternak AL, Erwin AL, Mason NT, Eng C, Hicks JK.

Cleve Clin J Med. 2020 Feb;87(2):91-99. doi: 10.3949/ccjm.87a.19073. Review.

2.

Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications.

Marcath LA, Pasternak AL, Hertz DL.

Pharmacogenomics J. 2019 Dec;19(6):501-515. doi: 10.1038/s41397-019-0105-1. Epub 2019 Oct 15. Review.

PMID:
31616046
3.

Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.

Pasternak AL, Kidwell KM, Dempsey JM, Gersch CL, Pesch A, Sun Y, Rae JM, Hertz DL, Park JM.

Pharmacogenomics. 2019 Apr;20(6):421-432. doi: 10.2217/pgs-2019-0002. Epub 2019 Apr 15.

PMID:
30983501
4.

CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration.

Pasternak AL, Zhang L, Hertz DL.

Pharmacogenomics. 2018 Apr;19(6):563-576. doi: 10.2217/pgs-2018-0003. Epub 2018 Apr 9. Review.

PMID:
29629825
5.

Germline genetic variants with implications for disease risk and therapeutic outcomes.

Pasternak AL, Ward KM, Luzum JA, Ellingrod VL, Hertz DL.

Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8. Review.

6.

Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy.

Hertz DL, Luzum JA, Pasternak AL, Ward KM, Zhu HJ, Rae JM, Ellingrod VL.

Pharmacogenomics. 2017 Jul 26. doi: 10.2217/pgs-2017-0107. [Epub ahead of print]

PMID:
28745551
7.

The impact of the UGT1A1*60 allele on bilirubin serum concentrations.

Pasternak AL, Crews KR, Caudle KE, Smith C, Pei D, Cheng C, Broeckel U, Gaur AH, Hankins J, Relling MV, Haidar CE.

Pharmacogenomics. 2017 Jan;18(1):5-16. doi: 10.2217/pgs-2016-0135. Epub 2016 Dec 14.

PMID:
27967321
8.

Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.

Pasternak AL, Link NA, Richardson CM, Rose PG.

Pharmacotherapy. 2016 Jul;36(7):723-30. doi: 10.1002/phar.1769. Epub 2016 Jun 30.

PMID:
27196693

Supplemental Content

Loading ...
Support Center